During a study conducted in Argentina, the high efficacy of the Russian anti-vaccine Sputnik V was confirmed in people over 60 years of age.

Published:

1 November 2021 09:54 GMT

More than 660,000 people have been vaccinated with Sputnik V and Astrogeneka and Sinoform drugs and participated in the research.

The Russian Direct Investment Fund (RDIF) says a study by the Ministry of Health in the city of Buenos Aires has confirmed the high efficacy of the Russian vaccine against the Sputnik V corona virus for the protection of people over 60 years of age. Monday.).

More than 660,000 people have participated in research on vaccinated with Sputnik V and Astrogeneca and Sinoform, the results Published In the Journal of the American Medical Association (JAMA) at the end of October.

Most participants were vaccinated with Sputnik V (63.5%).

Experts determined that the complete vaccine (two doses) helped to reduce one 88.1% Corona is associated with infection rate and reduction with virus 96.6% Death.

“The study reaffirms the excellent performance of Sputnik V. To protect the elderly“, Reads the report of the RDIF responsible for the distribution and sale of the drug.

In this context, the Russian Direct Investment Fund recalled the results of another study conducted by the Ministry of Health of the State of Buenos Aires in June this year, according to which the single-dose Sputnik light vaccine (first component Sputnik V) is 78.6% to 83.7% effective for the protection of people aged 60 to 79 years.

If you found it interesting, please share it with your friends!